Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-08-09
2010-11-23
Bradley, Christina (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07838490
ABSTRACT:
The present invention relates to methods and compositions for regulating vascular permeability. The present invention relates to methods and compositions for blocking proteins and signal transduction pathways involved in increasing vascular permeability.
REFERENCES:
Feng et al. (“Regulation of the Cool/Pix proteins: key binding partners of the Cdc42/Rac targets, the p21-activated kinases.” J. Biol. Chem., 2002, 277, 5644-50).
Manser et al. (“PAK kinases are directly coupled to the PIX family of nucleotide exchange factors,” Mol. Cell., 1998, 1, 183-92).
“European Application No. 06801159.2 , Office Action mailed on Dec. 16, 2009”, 1 pg.
“New Zealand Application Serial No. 566134 , First Examination Report Mailed, Feb. 26, 2010”, 3 pgs.
“Pharmaceutical Management Agency LTDvCommissioner of Patents”, R.P.C., 116, High Court of New Zealand—Wellington Registry, (1999), 752-774.
“Abstracts PS 0035-0363”,Intensive Care Medicine, 32(1), (2006), 14-96.
“European Applicaion Serial No. 06801159.2, Search Report mailed on Sep. 18, 2009”, 12 pgs.
“International Application Serial No. PCT/US06/31229, International Search Report mailed Aug. 17, 2007”, 4 pgs.
“International Application Serial No. PCT/US06/31229, Written Opinion mailed Aug. 17, 2007”, 4 pgs.
Garcia, J. G. N., et al., “Sphingosine 1—phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement”,Journal of Clinical Investigation, 108(5);, (2001), 689-701.
Kiosses, W. B., et al., “A Dominant-Negative p65 PAK Peptide Inhibits Angiogenesis”,Circulation Research, 90(6), (2002), 697-702.
Stockton, R. A., et al., “p21-activated kinase regulates endothelial permeability through modulation of contractility”,Journal of Biological Chemistry, 279(45), (2004), 46621-46630.
Strohm, C., et al., “Inhibition of the ER-Kinase Cascade by PD98059 and U0126 Counteracts Ischemic Preconditioning in Pig Myocardium”,Journal of Cardiovascular Pharmacology™, 369(2), (2000), 218-229.
Vouret-Craviari, V., et al., “Modulation of Rho GTPase activity in endothelial cells by selective proteinase-activated receptor (PAR)agonists”,Journal of Thrombosis and Haemostatis, 1(5), (2003), 1103-1111.
Woolfolk, E., et al., “Intracellular Mechanisms Involved in Regulation of p-21 Activated Kinase by Angiotensin II in Vascular Smooth Muscle Cells”,Faseb Journal, 19( 4, Suppl. S, Part 1), (Abstract 376.6), (Mar. 2005), p. A663.
Schwartz Martin A.
Stockton Rebecca A.
Bradley Christina
Schwegman Lundberg & Woessner, P.A.
University of Virginia Patent Foundation
LandOfFree
Methods and compositions for inhibition of vascular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for inhibition of vascular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for inhibition of vascular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4179015